Apr 29 2011
Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, is proud to announce the launch in the U.S. of XTRA, the next-generation of Sorin's autotransfusion (ATS) device family.
“XTRA represents our most innovative and powerful system to date and is designed to meet the most demanding blood management program requirements for ensuring patient safety and improving surgical outcomes. We are looking forward to extensively offer the benefits of our new XTRA system to both patients and clinicians”
An autotransfusion system is a sophisticated piece of medical equipment that allows collection, processing and reinfusion of autologous blood during and after surgical interventions in many applications including cardiac, orthopedic, vascular, obstetrics, trauma and others, as well as preoperative sequestration of whole blood components.
Sorin's XTRA ATS System is the culmination of over 30 years of experience in ATS system design and manufacturing.
The XTRA builds on state-of-the-art technology, introducing innovative solutions through functional design, graphic color operator's interface and advanced data management. Building on the design of Sorin's C5 and S5 world's leading heart lung machines (HLM), the XTRA is an intuitive and powerful system, providing high quality end-product, fast processing and quietness during operation. A small volume disposable option also handles low blood volume loss typical in pediatrics and orthopedic cases.
Collecting and reinfusing autologous blood has gained renewed interest due to the increasing risks associated with donor blood transfusion. Blood recovered from a patient's own body reduces the risk of adverse reactions and infectious disease transmission, conserves blood supplies and provides cost savings.
"XTRA represents our most innovative and powerful system to date and is designed to meet the most demanding blood management program requirements for ensuring patient safety and improving surgical outcomes. We are looking forward to extensively offer the benefits of our new XTRA system to both patients and clinicians", said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.
Customers evaluating the system stated that '' XTRA is a step forward with respect to the state of the art in terms of innovation'', ''a futuristic device truly designed with the operator and patient in mind'', as well as '' a system perfectly inserted in Sorin Group's high quality and innovative products''.
After an extensive market assessment study conducted in the U.S. and over four thousand clinical cases successfully conducted worldwide to date, the XTRA ATS System has been recently showcased in the U.S. at the American Society of ExtraCorporeal Technology (AmSECT) 49th International Conference, New Orleans, LA on April 13-16, 2011.
SOURCE Sorin Group
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder